Clarity Pharmaceuticals (FRA:1F4) Beta: N/A (As of Jul. 07, 2026)


FRA:1F4 Clarity Pharmaceuticals Ltd FRA:1F4
13 GF Score
Price €1.64
! 2 Warning Signs
View Full Analysis

What is Clarity Pharmaceuticals Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-07), Clarity Pharmaceuticals's Beta is Not available.

Clarity Pharmaceuticals  (FRA:1F4) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)

Clarity Pharmaceuticals Beta Related Terms

Clarity Pharmaceuticals Beta Historical Data

* Premium members only.

The historical data trend for Clarity Pharmaceuticals's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clarity Pharmaceuticals Beta Chart

Clarity Pharmaceuticals Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Beta
0.00 0.00 0.00 0.00

Clarity Pharmaceuticals Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:1F4
13GF Score
Clarity Pharmaceuticals Ltd FRA:1F4
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clarity Pharmaceuticals Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Clarity Pharmaceuticals Business Description

Other Exchanges CLRPF:USACU6:Australia
Address 2-4 Cornwallis Street, Suite 212a, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, using its SAR Technology platform. Clarity's Targeted Copper Theranostic (TCT) platform of products utilize pairing of copper isotopes, specifically copper-64 (Cu-64 or 64Cu) for imaging and copper-67 Cu-67 or 67Cu) for therapy, which delivers accuracy and precision in the treatment of a range of cancers. The company's clinical development pipeline includes SAR-bisPSMA, SAR-Bombesin, and Sartate, in their different stages of development for the diagnosis and/or treatment of various cancers. Clarity operates in a single segment, which is the development of radiopharmaceuticals. Geographically, it operates in Australia and the United States.
13GF Score

Get the complete analysis for FRA:1F4

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.64
Price